Please ensure Javascript is enabled for purposes of website accessibility

Osiris’ fourth-quarter results improve

Osiris Therapeutics Inc., of Columbia, a biotechnology company that uses adult stem cell therapy to treat damaged tissue, reported fourth-quarter net income of $5 million, or 15 cents per diluted share, on revenue of $11 million, versus net income of $4.4 million, or 13 cents per diluted share, on revenue of $10.8 million for the same period in 2010.

The company attributed the improvements to payments received from collaboration agreements with other pharmaceutical companies and the U.S. Department of Defense. It also said it spent less on research and development in fourth-quarter 2011 than in the prior-year period.